APC Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.05 1 Month 0.00 0.00
Volume 50000 1 Year 0.01 25.00
52 Week High 0.10
52 Week Low 0.04
APC Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
KLM 0.02 100.00%
XOP 0.02 100.00%
ADE 0.02 100.00%
ITM 0.04 100.00%
ITM 0.04 100.00%
ITM 0.04 100.00%
BVQ 0.02 100.00%
RUN 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
More..
CVE Canada Top Losers Stocks
HRC 0.00 -100.00%
HRC 0.00 -100.00%
HRC 0.00 -100.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BRL 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

Advanced Proteome Therpt (CVE: APC)

APC Technical Analysis 3
As on 19th Sep 2017 APC Share Price closed @ 0.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.06 & Sell for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
APC Target for September
1st Target up-side 0.07
2nd Target up-side 0.07
3rd Target up-side 0.07
1st Target down-side 0.05
2nd Target down-side 0.05
3rd Target down-side 0.05
APC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.advancedproteome.com
APC Address
APC
BioSquare
Suite 113
Boston, MA 02118
United States
Phone: 617-638-0340
Fax: 617-638-0341
APC Latest News
Interactive Technical Analysis Chart Advanced Proteome Therpt ( APC CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Advanced Proteome Therpt
APC Business Profile
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.